BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200. [PMID: 15918147 DOI: 10.1055/s-2005-871198] [Cited by in Crossref: 619] [Cited by in F6Publishing: 549] [Article Influence: 38.7] [Reference Citation Analysis]
Number Citing Articles
1 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006.] [Reference Citation Analysis]
2 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512-527. [PMID: 23313965 DOI: 10.1053/j.gastro.2013.01.002] [Cited by in Crossref: 395] [Cited by in F6Publishing: 359] [Article Influence: 49.4] [Reference Citation Analysis]
3 Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology. 2011;81 Suppl 1:111-115. [PMID: 22212944 DOI: 10.1159/000333270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
4 Li Y, Yan C, Weng S, Shi Z, Sun H, Chen J, Xu X, Ye R, Hong J. Texture analysis of multi-phase MRI images to detect expression of Ki67 in hepatocellular carcinoma. Clin Radiol 2019;74:813.e19-27. [PMID: 31362887 DOI: 10.1016/j.crad.2019.06.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
5 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3318] [Article Influence: 404.7] [Reference Citation Analysis]
6 Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D’onofrio M, Guglielmi A. Is Liver Resection Justified in Advanced Hepatocellular Carcinoma? Results of an Observational Study in 464 Patients. J Gastrointest Surg 2009;13:1313-20. [DOI: 10.1007/s11605-009-0903-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
7 Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One. 2013;8:e68203. [PMID: 23874541 DOI: 10.1371/journal.pone.0068203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
8 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 145] [Article Influence: 21.9] [Reference Citation Analysis]
9 Mori S, Kita J, Kato M, Shimoda M, Kubota K. Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy. Am J Surg 2015;209:187-93. [PMID: 24950991 DOI: 10.1016/j.amjsurg.2014.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver 2014;8:662-8. [PMID: 25368754 DOI: 10.5009/gnl13392] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
12 Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer 2018;124:3084-104. [DOI: 10.1002/cncr.31257] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
13 Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, Yu HC, Tsay FW, Wang HM, Tsai HC, Cheng JS. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One 2014;9:e92784. [PMID: 24824520 DOI: 10.1371/journal.pone.0092784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
14 Lewandowski RJ, Salem R. Microwave or radiofrequency ablation: clinically equivalent? The Lancet Gastroenterology & Hepatology 2018;3:291-2. [DOI: 10.1016/s2468-1253(18)30046-3] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 226] [Article Influence: 21.1] [Reference Citation Analysis]
17 Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee FY, Huo TI. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 2013;20:2035-42. [PMID: 23306955 DOI: 10.1245/s10434-012-2847-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 West CA, Black AP, Mehta AS. Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 93-107. [DOI: 10.1007/978-3-030-21540-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Dai F, Zhang X, Shen W, Chen J, Liu L, Gao G. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors. Onco Targets Ther 2015;8:2601-11. [PMID: 26451117 DOI: 10.2147/OTT.S87931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
20 Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc. 2010;42:4582-4584. [PMID: 21168742 DOI: 10.1016/j.transproceed.2010.09.147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
21 Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49:581-588. [PMID: 18602719 DOI: 10.1016/j.jhep.2008.03.032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
22 Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142:957-966.e12. [PMID: 22202459 DOI: 10.1053/j.gastro.2011.12.039] [Cited by in Crossref: 185] [Cited by in F6Publishing: 183] [Article Influence: 18.5] [Reference Citation Analysis]
23 Xu LT, Zhou ZH, Lin JH, Chen Z, Wang K, Wang P, Zhu XY, Shen YH, Meng ZQ, Liu LM. Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Eur J Surg Oncol. 2011;37:245-251. [PMID: 21195578 DOI: 10.1016/j.ejso.2010.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
24 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
25 Montasser MF, Shaker MK, Albreedy AM, Montasser IF, El Dorry A. Risk factors for early intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma in Egyptian patients. J Dig Dis 2014;15:676-83. [PMID: 25214183 DOI: 10.1111/1751-2980.12190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
27 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Muhi A, Ichikawa T, Motosugi U, Sano K, Fatima Z, Matsuda M, Fujii H, Enomoto N, Araki T. Diffusion-weighted imaging of hepatocellular carcinoma for predicting early recurrence and survival after hepatectomy. Hepatol Int 2013;7:662-8. [PMID: 26201799 DOI: 10.1007/s12072-012-9383-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Wang H, Li Y, Lu J, Qiu M, Cheng D, Zhang X, Yuan W. Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice. Biomed Pharmacother 2021;140:111775. [PMID: 34062413 DOI: 10.1016/j.biopha.2021.111775] [Reference Citation Analysis]
30 Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM. [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol 2007;13:530-42. [PMID: 18159151 DOI: 10.3350/kjhep.2007.13.4.530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
31 Aitken K, Hawkins M. The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours. Clinical Oncology 2014;26:569-80. [DOI: 10.1016/j.clon.2014.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S67-S71. [PMID: 21594967 DOI: 10.1002/lt.22340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
33 Yan C, Yang Q, Huo X, Li H, Zhou L, Gong Z. Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep 2017;7:45796. [PMID: 28378824 DOI: 10.1038/srep45796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Hsueh KC, Lee TY, Kor CT, Chen TM, Chang TM, Yang SF, Hsieh CB. The role of liver transplantation or resection for patients with early hepatocellular carcinoma. Tumour Biol. 2016;37:4193-4201. [PMID: 26490991 DOI: 10.1007/s13277-015-4243-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
35 Kim HR, Cheon SH, Rha SY, Lee S, Han KH, Chon CY, Lee JD, Sung JS, Chung HC. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia Pac J Clin Oncol. 2011;7:258-269. [PMID: 21884437 DOI: 10.1111/j.1743-7563.2011.01425.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
36 Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Takahashi K. Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound in Medicine & Biology 2015;41:3070-8. [DOI: 10.1016/j.ultrasmedbio.2015.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
37 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
38 Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol 2021:S0748-7983(21)00407-8. [PMID: 33902956 DOI: 10.1016/j.ejso.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Scatton O, Zalinski S, Terris B, Lefevre JH, Casali A, Massault PP, Conti F, Calmus Y, Soubrane O. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl. 2008;14:779-788. [PMID: 18508370 DOI: 10.1002/lt.21431] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
40 Zhao H, Hua Y, Dai T, He J, Tang M, Fu X, Mao L, Jin H, Qiu Y. Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma. Eur J Radiol 2017;88:32-40. [PMID: 28189206 DOI: 10.1016/j.ejrad.2016.12.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
41 Luk JM, Zhang Q, Lee NP, Wo JY, Leung PP, Liu L, Hu M, Cheung K, Hui C, Lau GK, Fan S. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Int 2007;27:548-57. [DOI: 10.1111/j.1478-3231.2007.01452.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
42 Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim DY. Outcome after curative resection for a huge hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg. 2009;198:693-701. [PMID: 19268907 DOI: 10.1016/j.amjsurg.2008.09.019] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
43 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
44 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
45 Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20:3754-3760. [PMID: 23884750 DOI: 10.1245/s10434-013-3074-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
46 Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:93-9. [PMID: 26093657 DOI: 10.1007/s00262-015-1728-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
47 Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, Park KM, Lee SG, Lim YS, Lee HC. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2010;17:869-877. [PMID: 20033326 DOI: 10.1245/s10434-009-0788-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
48 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015;7:566-74. [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
49 Lee M, Chang Y, Oh S, Cho YY, Jung DE, Kim HH, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yi NJ, Lee KW, Lee DH, Lee JM, Yoon JH, Suh KS, Kim YJ. Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. Gut Liver 2018;12:571-82. [PMID: 29730905 DOI: 10.5009/gnl17365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, Toombs B, Round M, Moore W, Mieles L. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl. 2010;16:289-299. [PMID: 20209588 DOI: 10.1002/lt.21994] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
51 Ou HY, Cheng YF, Chuang YH, Hsu HW, Chen CL, Lazo MZ, Weng CC, Yu CY, Tsang LL, Huang TL, Tong YS. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. Dig Dis Sci. 2019;. [PMID: 31732907 DOI: 10.1007/s10620-019-05951-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ha SY, Paik YH, Yang JW, Lee MJ, Bae H, Park CK. NADPH Oxidase 1 and NADPH Oxidase 4 Have Opposite Prognostic Effects for Patients with Hepatocellular Carcinoma after Hepatectomy. Gut Liver 2016;10:826-35. [PMID: 27282266 DOI: 10.5009/gnl15543] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
53 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
54 Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R. Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg 2010;34:2146-54. [PMID: 20411387 DOI: 10.1007/s00268-010-0583-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
55 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
56 Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 2014;53:39-45. [PMID: 24777354 DOI: 10.3413/nukmed-0622-13-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
57 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50. [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 86] [Article Influence: 13.7] [Reference Citation Analysis]
58 Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35. [PMID: 22576353 DOI: 10.1002/hep.25832] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 23.6] [Reference Citation Analysis]
59 Hu HT, Shen SL, Wang Z, Shan QY, Huang XW, Zheng Q, Xie XY, Lu MD, Wang W, Kuang M. Peritumoral tissue on preoperative imaging reveals microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Abdom Radiol (NY) 2018;43:3324-30. [PMID: 29845312 DOI: 10.1007/s00261-018-1646-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
60 Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, Steel J, Marsh JW, Tsung A. Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma. HPB (Oxford). 2013;15:210-217. [PMID: 23374361 DOI: 10.1111/j.1477-2574.2012.00541.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
61 Canter RJ, Patel SA, Kennedy T, D'Angelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, DeMatteo RP, Abt PL. Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the milan criteria treated with liver transplantation versus partial hepatectomy. Am J Clin Oncol 2011;34:466-71. [PMID: 20938319 DOI: 10.1097/COC.0b013e3181ec63dd] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013;19:8861-8866. [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
63 Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med 2020;2:337-42. [PMID: 33330829 DOI: 10.35772/ghm.2020.01059] [Reference Citation Analysis]
64 Zhang M, Chua MS, Hu J, Li H, Zhang S, Wu L, Han B. High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection. Cancer Manag Res 2019;11:10623-32. [PMID: 31908534 DOI: 10.2147/CMAR.S230386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci. 2013;58:1916-1922. [PMID: 23456506 DOI: 10.1007/s10620-013-2609-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
66 Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160. [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
67 Hasegawa K, Imamura H, Ijichi M, Matsuyama Y, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462). J Gastrointest Surg. 2008;12:858-866. [PMID: 18202893 DOI: 10.1007/s11605-007-0464-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
68 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
69 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 747] [Cited by in F6Publishing: 678] [Article Influence: 57.5] [Reference Citation Analysis]
70 Doussot A, Lim C, Lahat E, Salloum C, Osseis M, Gavara CG, Levesque E, Feray C, Compagnon P, Azoulay D. Complications after Hepatectomy for Hepatocellular Carcinoma Independently Shorten Survival: A Western, Single-Center Audit. Ann Surg Oncol 2017;24:1569-78. [DOI: 10.1245/s10434-016-5746-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
71 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol. 2015;49:242-249. [PMID: 24714185 DOI: 10.1097/mcg.0000000000000133] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
72 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
73 Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 2011;13:783-91. [PMID: 21999591 DOI: 10.1111/j.1477-2574.2011.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
74 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol. 2015;7:1020-1029. [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 13.0] [Reference Citation Analysis]
75 LE PH, Huang SC, Lim SN, Chou CH, Yeh TS, Chen TC, Yen TH, Su MY, Chiu CT, Yeh CT, Lin WR. Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma. Oncol Lett 2014;7:1430-8. [PMID: 24765151 DOI: 10.3892/ol.2014.1966] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
76 Li P, Huang W, Wang F, Ke YF, Gao L, Shi KQ, Zhou MT, Chen BC. Nomograms based on inflammatory biomarkers for predicting tumor grade and micro-vascular invasion in stage I/II hepatocellular carcinoma. Biosci Rep. 2018;38. [PMID: 30254101 DOI: 10.1042/bsr20180464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
77 Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; for the Panel of Experts in HCC-Design Clinical Trials. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI: Journal of the National Cancer Institute 2008;100:698-711. [DOI: 10.1093/jnci/djn134] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 1082] [Article Influence: 89.7] [Reference Citation Analysis]
78 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
80 Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, Greig PD, Grant DR. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633-1639. [PMID: 16794527 DOI: 10.1097/01.tp.0000226069.66819.7e] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
81 Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015;7:1347-54. [PMID: 26052380 DOI: 10.4254/wjh.v7.i10.1347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
82 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. Ann Surg Oncol. 2019;26:4126-4133. [PMID: 31359277 DOI: 10.1245/s10434-019-07646-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
83 Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
84 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
85 Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100-106. [PMID: 24503764 DOI: 10.1097/01.tp.0000441090.39840.b0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
86 Méndez-sánchez N. Hepatology highlights. Annals of Hepatology 2016;15:4-5. [DOI: 10.5604/16652681.1184184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Merle P, Mornex F. [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]. Cancer Radiother 2011;15:69-71. [PMID: 21237690 DOI: 10.1016/j.canrad.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
88 Huang SF, Wu HD, Chen YT, Murthy SR, Chiu YT, Chang Y, Chang IC, Yang X, Loh YP. Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma. Tumour Biol 2016;37:9745-53. [PMID: 26803519 DOI: 10.1007/s13277-016-4814-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
89 Motomura T, Ono Y, Shirabe K, Fukuhara T, Konishi H, Mano Y, Toshima T, Yoshiya S, Muto J, Ikegami T, Yoshizumi T, Maehara Y. Neither MICA Nor DEPDC5 Genetic Polymorphisms Correlate with Hepatocellular Carcinoma Recurrence following Hepatectomy. HPB Surg 2012;2012:185496. [PMID: 23132957 DOI: 10.1155/2012/185496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kwon HJ, Byun JH, Kim JY, Hong GS, Won HJ, Shin YM, Kim PN. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images. Abdom Imaging. 2015;40:64-75. [PMID: 24997560 DOI: 10.1007/s00261-014-0188-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
91 Zhou J, Ling G, Cao J, Ding X, Liao X, Wu M, Zhou X, Xu H, Long Q. Transcatheter Intra-Arterial Infusion Combined with Interventional Photothermal Therapy for the Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2020;15:1373-85. [PMID: 32184592 DOI: 10.2147/IJN.S233989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 873] [Article Influence: 188.2] [Reference Citation Analysis]
93 Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014;2:839-44. [PMID: 25054055 DOI: 10.3892/mco.2014.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
94 Lu WP, Dong JH. Hepatectomy for hepatocellular carcinoma in the era of liver transplantation. World J Gastroenterol 2014;20:9237-44. [PMID: 25071316 DOI: 10.3748/wjg.v20.i28.9237] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
95 Felga G, Evangelista A, Salvalaggio P, Curvelo L, Della Guardia B, Almeida M, Afonso R, Ferraz-neto B. Hepatocellular Carcinoma Recurrence Among Liver Transplant Recipients Within the Milan Criteria. Transplantation Proceedings 2012;44:2459-61. [DOI: 10.1016/j.transproceed.2012.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
96 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
97 Ha SY, Song DH, Hwang SH, Cho SY, Park CK. Expression of prothymosin alpha predicts early recurrence and poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2015;14:171-7. [PMID: 25865690 DOI: 10.1016/s1499-3872(14)60326-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
98 Poon RT. Liver Transplantation for Solitary Hepatocellular Carcinoma Less than 3 cm in Diameter in Child A Cirrhosis. Dig Dis 2007;25:334-40. [DOI: 10.1159/000106914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
99 Beichel R, Bornik A, Bauer C, Sorantin E. Liver segmentation in contrast enhanced CT data using graph cuts and interactive 3D segmentation refinement methods. Med Phys 2012;39:1361-73. [PMID: 22380370 DOI: 10.1118/1.3682171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
100 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 191] [Article Influence: 40.3] [Reference Citation Analysis]
101 Shin SK, Kim YS, Shim YS, Choi SJ, Park SH, Jung DH, Kwon OS, Choi DJ, Kim JH. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore) 2017;96:e7761. [PMID: 28816953 DOI: 10.1097/MD.0000000000007761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
102 Xu X, Liu C, Qu K, Song Y, Zhang P, Zhang Y. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2014;13:234-41. [DOI: 10.1016/s1499-3872(14)60037-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
103 Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Fujimoto Y, Ogawa K, Mori A, Hammad A, Hatano E, Uemoto S. Muscle Steatosis is an Independent Predictor of Postoperative Complications in Patients with Hepatocellular Carcinoma. World J Surg 2016;40:1959-68. [PMID: 27071610 DOI: 10.1007/s00268-016-3504-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
104 Sapisochin G, de Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol. 2014;6:766-775. [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
105 Tao J, Ji J, Li X, Ding N, Wu H, Liu Y, Wang XW, Calvisi DF, Song G, Chen X. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget 2015;6:6977-88. [PMID: 25762642 DOI: 10.18632/oncotarget.3166] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
106 Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo N, Makuuchi M. Effectiveness of Hepatic Resection for Early-stage Hepatocellular Carcinoma in Cirrhotic Patients: Subgroup Analysis according to Milan Criteria. Japanese Journal of Clinical Oncology 2007;37:287-95. [DOI: 10.1093/jjco/hym025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
107 Gurusamy KS, Li J, Vaughan J, Sharma D, Davidson BR. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2012;:CD007338. [PMID: 22592720 DOI: 10.1002/14651858.CD007338.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
108 Wang J, Changchien C, Hu T, Lee C, Kee K, Lin C, Chen C, Chen T, Huang Y, Lu S. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 patients. European Journal of Cancer 2008;44:1000-6. [DOI: 10.1016/j.ejca.2008.02.018] [Cited by in Crossref: 142] [Cited by in F6Publishing: 142] [Article Influence: 10.9] [Reference Citation Analysis]
109 Palesty JA, Al-Kasspooles M, Gibbs JF. Patient selection for surgical management of primary and metastatic liver cancers: current perspectives. Semin Intervent Radiol 2006;23:13-20. [PMID: 21326716 DOI: 10.1055/s-2006-939837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Yang Q, Yan C, Gong Z. Interaction of hepatic stellate cells with neutrophils and macrophages in the liver following oncogenic kras activation in transgenic zebrafish. Sci Rep 2018;8:8495. [PMID: 29855567 DOI: 10.1038/s41598-018-26612-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
111 Hu YW, Chen ZP, Hu XM, Zhao JY, Huang JL, Ma X, Li SF, Qiu YR, Wu XJ, Sha YH, Gao JJ, Wang YC, Zheng L, Wang Q. The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis. Apoptosis 2015;20:1321-37. [PMID: 26201458 DOI: 10.1007/s10495-015-1153-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
112 Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open 2019;2:e1910326. [PMID: 31469395 DOI: 10.1001/jamanetworkopen.2019.10326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
113 Dodson RM, He J, Pawlik TM. Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options. Future Oncology 2014;10:587-607. [DOI: 10.2217/fon.13.225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
114 Scherber PR, Gäbelein G, Eisele RM, Igna D, Glanemann M. [Early stage liver cancer : Hepatocellular carcinoma]. Chirurg 2018;89:281-8. [PMID: 29075797 DOI: 10.1007/s00104-017-0538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Ng L, Kwan V, Chow A, Yau TC, Poon RT, Pang R, Law WL. Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients. BMC Cancer 2019;19:713. [PMID: 31324164 DOI: 10.1186/s12885-019-5919-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy. J Gastrointest Surg 2009;13:325-33. [DOI: 10.1007/s11605-008-0711-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
117 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 9.3] [Reference Citation Analysis]
118 Jun L, Zhenlin Y, Renyan G, Yizhou W, Xuying W, Feng X, Yong X, Kui W, Jian L, Dong W, Hongyang W, Lehua S, Mengchao W, Feng S. Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist 2012;17:963-9. [PMID: 22653882 DOI: 10.1634/theoncologist.2011-0447] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
119 Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:286-294. [PMID: 23742774 DOI: 10.1016/s1499-3872(13)60046-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
120 Mergental H, Adam R, Ericzon B, Kalicinski P, Mühlbacher F, Höckerstedt K, Klempnauer JL, Friman S, Broelsch CE, Mantion G, Fernandez-sellez C, van Hoek B, Fangmann J, Pirenne J, Muiesan P, Königsrainer A, Mirza DF, Lerut J, Detry O, Le Treut Y, Mazzaferro V, Löhe F, Berenguer M, Clavien P, Rogiers X, Belghiti J, Kóbori L, Burra P, Wolf P, Schareck W, Pisarski P, Foss A, Filipponi F, Krawczyk M, Wolff M, Langrehr JM, Rolles K, Jamieson N, Hop WC, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. Journal of Hepatology 2012;57:297-305. [DOI: 10.1016/j.jhep.2012.03.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
121 Lopez PM, Patel P, Uva P, Villanueva A, Llovet JM. Current management of liver cancer. European Journal of Cancer Supplements 2007;5:444-6. [DOI: 10.1016/s1359-6349(07)70093-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
122 Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, Wu MC, Lau WY, Cheng SQ. Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. Ann Surg Oncol. 2016;23:1344-1351. [PMID: 26714945 DOI: 10.1245/s10434-015-5008-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
123 Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl 2006;12:1741-3. [PMID: 17133574 DOI: 10.1002/lt.20908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
124 Jung KS, Kim JH, Kim SU, Song K, Kim BK, Park JY, Kim DY, Ahn SH, Moon DC, Song IJ, Choi GH, Park YN, Han KH. Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: development and validation of a predictive model. PLoS One 2014;9:e99167. [PMID: 24910997 DOI: 10.1371/journal.pone.0099167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
125 Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: A randomized double-blind placebo-controlled study. J Gastroenterol. 2015;50:191-202. [PMID: 24728665 DOI: 10.1007/s00535-014-0956-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
126 Jun BG, Lee WC, Jang JY, Jeong SW, Chang Y, Lee SH, Kim YD, Kim SG, Cheon GJ, Kim YS, Kim HS, Jin SY. Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection. PLoS One 2020;15:e0227440. [PMID: 31940413 DOI: 10.1371/journal.pone.0227440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
127 Díaz-Rodríguez E, El-Mallah AM, Sanz E, Pandiella A. Antitumoral effect of Ocoxin in hepatocellular carcinoma. Oncol Lett 2017;14:1950-8. [PMID: 28781639 DOI: 10.3892/ol.2017.6440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
128 Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando). 2010;24:11-17. [PMID: 19942101 DOI: 10.1016/j.trre.2009.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
129 Seo YS, Kim YJ, Kim MS, Suh KS, Kim SB, Han CJ, Kim YJ, Jang WI, Kang SH, Tchoe HJ. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. Medicine (Baltimore). 2016;95:e3527. [PMID: 27124061 DOI: 10.1097/MD.0000000000003527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
130 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547. [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 214] [Article Influence: 16.7] [Reference Citation Analysis]
131 Yan J, Tan C, Gu F, Jiang J, Xu M, Huang X, Dai Z, Wang Z, Fan J, Zhou J. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver Transpl. 2013;19:507-520. [PMID: 23408515 DOI: 10.1002/lt.23619] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
132 Wang S, Chuang S, Lee K. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study: Sorafenib prevents early HCC recurrence. Hepatol Res 2014;44:523-31. [DOI: 10.1111/hepr.12159] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
133 Hoyos S, Escobar J, Cardona D, Guzmán C, Mena A, Osorio G, Pérez C, Restrepo JC, Correa G. Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study. Annals of Hepatology 2015;14:58-63. [DOI: 10.1016/s1665-2681(19)30801-4] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
134 Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin. 2010;31:1643-1648. [PMID: 21102481 DOI: 10.1038/aps.2010.124] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
135 Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:124-30. [DOI: 10.1007/s00534-007-1296-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
136 Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, Castells L, Dopazo C, Castro E, Caralt M, Balsells J. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2007;39:2308-10. [PMID: 17889173 DOI: 10.1016/j.transproceed.2007.06.042] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
137 Lau KN, Swan RZ, Sindram D, Martinie JB, Iannitti DA. Hepatic tumor ablation: application in a community hospital setting. Surg Oncol Clin N Am 2011;20:455-66, viii. [PMID: 21640915 DOI: 10.1016/j.soc.2011.01.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Ha SY, Choi M, Lee T, Park CK. The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy. Cancer Res Treat. 2016;48:180-189. [PMID: 25797572 DOI: 10.4143/crt.2014.321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
139 Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016;5:128-138. [PMID: 27386431 DOI: 10.1159/000367754] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 11.4] [Reference Citation Analysis]
140 Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842-8. [PMID: 20890660 DOI: 10.1007/s10903-010-9395-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
141 Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery. 2010;147:676-685. [PMID: 20004441 DOI: 10.1016/j.surg.2009.10.043] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 7.6] [Reference Citation Analysis]
142 Lee KK, Kim DG, Moon IS, Lee MD, Park JH. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010;101:47-53. [PMID: 19798686 DOI: 10.1002/jso.21415] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 8.4] [Reference Citation Analysis]
143 Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14:3452-3460. [PMID: 18567070 DOI: 10.3748/wjg.14.3452] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
144 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
145 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
146 Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget 2015;6:24132-47. [PMID: 26125229 DOI: 10.18632/oncotarget.4432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
147 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 38.3] [Reference Citation Analysis]
148 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
149 Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D, Madariaga J, Dervenis C. Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria. HPB (Oxford) 2009;11:551-8. [PMID: 20495706 DOI: 10.1111/j.1477-2574.2009.00084.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
150 Ntomi V, Paspala A, Schizas D. Novel Techniques in the Surgical Management of Hepatocellular Carcinoma. In: Lasfar A, editor. Liver Cancer. IntechOpen; 2018. [DOI: 10.5772/intechopen.79982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Tamaki N, Kuno A, Matsuda A, Tsujikawa H, Yamazaki K, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Korenaga M, Mizokami M, Kurosaki M, Sakamoto M, Narimatsu H, Izumi N. Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. Sci Rep 2017;7:244. [PMID: 28325920 DOI: 10.1038/s41598-017-00357-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
152 Wang F, Zhao W, Gao Y, Zhou J, Li H, Zhang G, Guo D, Xie C, Li J, Yin Z, Zhang J. CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis. J Exp Clin Cancer Res 2019;38:286. [PMID: 31272499 DOI: 10.1186/s13046-019-1297-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
153 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896.ecolletion] [Reference Citation Analysis]
154 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
155 Yuan D, Gao Z, Zhao J, Zhang H, Wang J. 125I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. Brachytherapy 2019;18:521-9. [DOI: 10.1016/j.brachy.2019.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
156 Kumar A, Srivastava DN, Bal C. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. J Vasc Interv Radiol 2006;17:157-61. [PMID: 16415146 DOI: 10.1097/01.rvi.0000195321.20579.f2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl. 2014;20:291-297. [PMID: 24734314 DOI: 10.1002/lt.23798] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
158 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
159 Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47:9-15. [PMID: 23482400 DOI: 10.4132/KoreanJPathol. 2013.47.1.9] [Reference Citation Analysis]
160 Luo C, Pu J, Liu F, Long X, Wang C, Wei H, Tang Q. MicroRNA-200c expression is decreased in hepatocellular carcinoma and associated with poor prognosis. Clin Res Hepatol Gastroenterol 2019;43:715-21. [PMID: 30962170 DOI: 10.1016/j.clinre.2019.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
161 Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, Zheng MH. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opin Ther Targets. 2015;19:675-685. [PMID: 25547779 DOI: 10.1517/14728222.2014.997711] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
162 Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330-339. [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 17.2] [Reference Citation Analysis]
163 Crocetti L, Lencioni R. Thermal ablation of hepatocellular carcinoma. Cancer Imaging 2008;8:19-26. [PMID: 18331969 DOI: 10.1102/1470-7330.2008.0004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
164 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
165 Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, Bogart E, Le Deley MC, Steen V, Lacornerie T, Peiffert D, Mirabel X. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020;107:116-125. [PMID: 32001057 DOI: 10.1016/j.ijrobp.2019.12.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 19.0] [Reference Citation Analysis]
166 Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl. 2007;13:S44-S47. [PMID: 17969068 DOI: 10.1002/lt.21330] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
167 Pham AD, Vaz K, Ardalan ZS, Sinclair M, Apostolov R, Gardner S, Majeed A, Mishra G, Kam NM, Patwala K, Kutaiba N, Arachchi N, Bell S, Dev AT, Lubel JS, Nicoll AJ, Sood S, Kemp W, Roberts SK, Fink M, Testro AG, Angus PW, Gow PJ. Clinical outcomes of patients with two small hepatocellular carcinomas. WJH 2021;13:1439-49. [DOI: 10.4254/wjh.v13.i10.1439] [Reference Citation Analysis]
168 Taketomi A, Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K, Maehara Y. A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surg Today. 2013;43:289-292. [PMID: 23266750 DOI: 10.1007/s00595-012-0462-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
169 Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J Hepatol. 2005;43:377-380. [PMID: 16005537 DOI: 10.1016/j.jhep.2005.06.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
170 Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, Martinie JB, Russo MW, Iannitti DA. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014;16:1102-9. [PMID: 24964271 DOI: 10.1111/hpb.12300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
171 Hwang HS, An J, Kang HJ, Oh B, Oh YJ, Oh JH, Kim W, Sung CO, Shim JH, Yu E. Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: Implications of S100P for Early Recurrence. Ann Surg Oncol 2021. [PMID: 33786678 DOI: 10.1245/s10434-021-09825-y] [Reference Citation Analysis]
172 Manzini G, Henne-Bruns D, Porzsolt F, Kremer M. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? BMJ Open Gastroenterol. 2017;4:e000129. [PMID: 28405349 DOI: 10.1136/bmjgast-2016-000129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
173 Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758-1767. [PMID: 17087938 DOI: 10.1053/j.gastro.2006.09.014] [Cited by in Crossref: 287] [Cited by in F6Publishing: 238] [Article Influence: 19.1] [Reference Citation Analysis]
174 Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727-736. [PMID: 22344899 DOI: 10.1002/lt.23413] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 8.2] [Reference Citation Analysis]
175 Poon RTP. Optimal Initial Treatment for Early Hepatocellular Carcinoma in Patients with Preserved Liver Function: Transplantation or Resection? Ann Surg Oncol 2007;14:541-7. [DOI: 10.1245/s10434-006-9156-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
176 Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, Li L, Ren S, Zhang M, Xu M. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res 2019;38:98. [PMID: 30795787 DOI: 10.1186/s13046-019-1041-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 39.0] [Reference Citation Analysis]
177 Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res 2016;8:297-302. [PMID: 26985249 DOI: 10.14740/jocmr2496w] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
178 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
179 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol. 2013;5:302-310. [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
180 Pascual S, Irurzun J, Zapater P, Such J, Sempere L, Carnicer F, Palazón JM, De La Iglesia P, Gil S, De España F, Perez-mateo M. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice: Surveillance for hepatocellular carcinoma. Liver International 2008;28:682-9. [DOI: 10.1111/j.1478-3231.2008.01710.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
181 Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, Del Val A, Pascasio JM. [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc). 2010;134:569-576. [PMID: 20036398 DOI: 10.1016/j.medcli.2009.10.042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
182 Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, Zhang Q, Chong Y, Hu B. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Brief Bioinform 2021:bbaa427. [PMID: 33515024 DOI: 10.1093/bib/bbaa427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. WJGO 2021;13:845-55. [DOI: 10.4251/wjgo.v13.i8.845] [Reference Citation Analysis]
184 Aigelsreiter A, Neumann J, Pichler M, Halasz J, Zatloukal K, Berghold A, Douschan P, Rainer F, Stauber R, Haybaeck J, Denk H, Lackner C. Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. Liver Int 2017;37:600-10. [PMID: 27885796 DOI: 10.1111/liv.13325] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
185 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
186 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 156] [Article Influence: 24.1] [Reference Citation Analysis]
187 Wei X, Li J, Xie H, Wang H, Wang J, Zhang X, Zhuang R, Lu D, Ling Q, Zhou L, Xu X, Zheng S. Chloride intracellular channel 1 participates in migration and invasion of hepatocellular carcinoma by targeting maspin. J Gastroenterol Hepatol. 2015;30:208-216. [PMID: 24989236 DOI: 10.1111/jgh.12668] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
188 Chen J, Wu M, Liu R, Li S, Gao R, Song B. Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis. PLoS One 2015;10:e0117661. [PMID: 25658359 DOI: 10.1371/journal.pone.0117661] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
189 Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology 2017;66:338-46. [DOI: 10.1016/j.jhep.2016.09.008] [Cited by in Crossref: 144] [Cited by in F6Publishing: 129] [Article Influence: 36.0] [Reference Citation Analysis]
190 Bhardwaj N, Perera MT, Silva MA. Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant 2016;2016:7926264. [PMID: 27413539 DOI: 10.1155/2016/7926264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
191 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 253] [Article Influence: 30.3] [Reference Citation Analysis]
192 Beaugrand M, Trinchet JC. Interventional radiology as a fine art. J Hepatol 2007;46:362-4. [PMID: 17239483 DOI: 10.1016/j.jhep.2007.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
193 Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8-17. [PMID: 22104564 DOI: 10.1097/sla.0b013e3182363ff9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 35] [Article Influence: 8.7] [Reference Citation Analysis]
194 Sun Z, Liang ST, Zhai XF, Lang QB, Zhou QH, Yue XQ, He J, Xu J, Zhu Y, Ling CQ. A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up. J Tradit Chin Med. 2012;32:156-163. [PMID: 22876437 DOI: 10.1016/s0254-6272(13)60005-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
195 Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol. 2011;17:5083-5088. [PMID: 22171142 DOI: 10.3748/wjg.v17.i46.5083] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
196 Lao L, Shen J, Tian H, Zhong G, Murray SS, Wang JC. Secreted phosphoprotein 24 kD (Spp24) inhibits growth of hepatocellular carcinoma in vivo. Environmental Toxicology and Pharmacology 2017;51:51-5. [DOI: 10.1016/j.etap.2017.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
197 Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, Su RG, Liang TB. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1429-1440. [PMID: 24770582 DOI: 10.1007/s00432-014-1684-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
198 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
199 Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
200 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
201 Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larson AC, Omary RA. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008;19:1483-9. [PMID: 18922400 DOI: 10.1016/j.jvir.2008.06.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 5.0] [Reference Citation Analysis]
202 Luo D, Li H, Yu H, Zhang M, Hu J, Jin C, Chua M, Han B. Predictive value of preoperative and postoperative peripheral lymphocyte difference in hepatitis B virus-related hepatocellular cancer patients: Based on the analysis of dynamic nomogram. J Surg Oncol 2020;122:1553-68. [PMID: 32862430 DOI: 10.1002/jso.26195] [Reference Citation Analysis]
203 Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L, Jia Y, Song C, Li ZP, Feng ST. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 2019;19:364. [PMID: 30999947 DOI: 10.1186/s12885-019-5574-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
204 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Forner A, Roayaie S. Clinical research in hepatocellular carcinoma: study design and endpoints. J Hepatol. 2009;50:850-853. [PMID: 19329214 DOI: 10.1016/j.jhep.2009.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Du Y, Cao GW. Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology. World J Gastroenterol 2012;18:3941-4. [PMID: 22912544 DOI: 10.3748/wjg.v18.i30.3941] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
207 Varela M, Forner A, Bruix J. Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure. Liver Transpl 2006;12:1445-7. [DOI: 10.1002/lt.20909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
208 Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis. Annals of Surgery 2015;261:947-55. [DOI: 10.1097/sla.0000000000000710] [Cited by in Crossref: 221] [Cited by in F6Publishing: 124] [Article Influence: 36.8] [Reference Citation Analysis]
209 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
210 Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol. 2011;18:2638-2646. [PMID: 21584831 DOI: 10.1245/s10434-011-1779-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
211 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016;22:7252-63. [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
212 Minami Y, Kudo M. Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. Liver Cancer 2015;4:106-14. [PMID: 26697413 DOI: 10.1159/000367733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
213 Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther. 2019;12:541-548. [PMID: 30666133 DOI: 10.2147/ott.s187357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
214 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975-981. [PMID: 19672926 DOI: 10.1002/bjs.6731] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 9.0] [Reference Citation Analysis]
215 Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20:4160-4166. [PMID: 24764654 DOI: 10.3748/wjg.v20.i15.4160] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
216 Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol. 2014;15:380-394. [PMID: 24838298 DOI: 10.1007/s11864-014-0291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
217 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1595] [Article Influence: 321.3] [Reference Citation Analysis]
218 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 240] [Article Influence: 43.3] [Reference Citation Analysis]
219 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
220 Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK, Kuznetsov VA. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol 2018;12:89-113. [PMID: 29117471 DOI: 10.1002/1878-0261.12153] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
221 Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging. 2012;37:215-230. [PMID: 21909721 DOI: 10.1007/s00261-011-9794-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
222 Abbate V, Marcantoni M, Giuliante F, Vecchio FM, Gatto I, Mele C, Saviano A, Arciuolo D, Gaetani E, Ferrari MC, Giarretta I, Ardito F, Riccardi L, Nicoletti A, Ponziani FR, Gasbarrini A, Pompili M, Pola R. HepPar1-Positive Circulating Microparticles Are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection. Int J Mol Sci 2017;18:E1043. [PMID: 28498353 DOI: 10.3390/ijms18051043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
223 Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;370:78-84. [PMID: 26472630 DOI: 10.1016/j.canlet.2015.09.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
224 Lv T, Jiang L, Yan L, Yang J, Li B, Wen T, Zeng Y, Wang W, Xu M. Multiple Tumors Located in the Same Section Are Associated with Better Outcomes After Hepatic Resection for HCC Patients Meeting the Milan Criteria. J Gastrointest Surg 2015;19:2207-14. [DOI: 10.1007/s11605-015-2959-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
225 Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22:1137-1151. [PMID: 19187872 DOI: 10.1016/j.bpg.2008.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
226 Li R, Deng Y, Liang J, Hu Z, Li X, Liu H, Wang G, Fu B, Zhang T, Zhang Q, Yang Y, Chen G, Liu W. Circular RNA circ-102,166 acts as a sponge of miR-182 and miR-184 to suppress hepatocellular carcinoma proliferation and invasion. Cell Oncol (Dordr) 2021;44:279-95. [PMID: 33034848 DOI: 10.1007/s13402-020-00564-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
227 Yu Z, Feng H, Sun X, Zhuo Y, Li M, Zhou Z, Huang L, Jiang Y, Zhu X, Zhang X, Le F, Zheng C, Cheng AS, Gao Y. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase. Sci Rep 2018;8:3891. [PMID: 29497076 DOI: 10.1038/s41598-018-22113-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
228 Wu L, Xu P, Rao S, Yang L, Chen C, Liu H, Fu C, Zeng M. ADCtotal ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma. J MagnReson Imaging. 2017;46:820-830. [PMID: 28276105 DOI: 10.1002/jmri.25617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
229 Popow J, Arnhof H, Bader G, Berger H, Ciulli A, Covini D, Dank C, Gmaschitz T, Greb P, Karolyi-özguer J, Koegl M, Mcconnell DB, Pearson M, Rieger M, Rinnenthal J, Roessler V, Schrenk A, Spina M, Steurer S, Trainor N, Traxler E, Wieshofer C, Zoephel A, Ettmayer P. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. J Med Chem 2019;62:2508-20. [DOI: 10.1021/acs.jmedchem.8b01826] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 21.5] [Reference Citation Analysis]
230 Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles HC, Maluf DG, Cotterell AH, Posner MP, Fisher RA. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119-126. [PMID: 18261500 DOI: 10.1016/j.amjmed.2007.09.020] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 8.0] [Reference Citation Analysis]
231 Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P;  Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43. [PMID: 19058754 DOI: 10.1016/s1470-2045(08)70284-5] [Cited by in Crossref: 1089] [Cited by in F6Publishing: 417] [Article Influence: 83.8] [Reference Citation Analysis]
232 Choi JH, Kim MJ, Park YK, Im JY, Kwon SM, Kim HC, Woo HG, Wang HJ. Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype. Oncotarget 2017;8:22903-16. [PMID: 28038442 DOI: 10.18632/oncotarget.14248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
233 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
234 Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. BMC Cancer 2018;18:1164. [PMID: 30477453 DOI: 10.1186/s12885-018-5099-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, Lee BH. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med 2016;5:3094-101. [PMID: 27709795 DOI: 10.1002/cam4.893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
236 Gao Z, Du G, Pang Y, Fu Z, Liu C, Liu Y, Zhou B, Kong D, Shi B, Jiang Z, Jin B. Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors. Medicine (Baltimore) 2017;96:e7426. [PMID: 28816936 DOI: 10.1097/MD.0000000000007426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
237 Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D, Ling C. Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer. 2012;11:39. [PMID: 22682366 DOI: 10.1186/1476-4598-11-39] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
238 Leong L. Ultrasound of living donor liver transplantation. Biomed Imaging Interv J 2006;2:e17. [PMID: 21614227 DOI: 10.2349/biij.2.2.e17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
239 Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, Benkö T. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017;22:215-21. [PMID: 28408731 DOI: 10.12659/aot.902595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
240 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 211] [Article Influence: 72.7] [Reference Citation Analysis]
241 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
242 Gül-Klein S, Kästner A, Haber PK, Krenzien F, Wabitsch S, Krannich A, Andreou A, Eurich D, Tacke F, Horst D, Pratschke J, Schmelzle M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. J Hepatocell Carcinoma 2021;8:133-43. [PMID: 33777855 DOI: 10.2147/JHC.S292010] [Reference Citation Analysis]
243 Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. Oncology 2007;72:52-7. [DOI: 10.1159/000111707] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
244 Andrew Schumacher P, Powell JJ, Macneill AJ, Buczkowski AK, Erb SR, Ho SG, Scudamore CH, Stembrecher UP, Weiss A, Yoshida E, Chung SW. Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. Annals of Hepatology 2010;9:23-32. [DOI: 10.1016/s1665-2681(19)31675-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
245 Lopci E, Torzilli G, Poretti D, de Neto LJS, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A. Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2015;42:1399-407. [DOI: 10.1007/s00259-015-3079-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
246 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007;245:51-8. [PMID: 17197965 DOI: 10.1097/01.sla.0000225255.01668.65] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 9.1] [Reference Citation Analysis]
247 Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541-1548. [PMID: 18422961 DOI: 10.1111/j.1440-1746.2008.05395.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 7.8] [Reference Citation Analysis]
248 Wang GZ, Zhang W, Fang ZT, Zhang W, Yang MJ, Yang GW, Li S, Zhu L, Wang LL, Zhang WS, Liu R, Qian S, Wang JH, Qu XD. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. J Cancer Res Clin Oncol 2014;140:1125-36. [PMID: 24756364 DOI: 10.1007/s00432-014-1659-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
249 Tsai W, Cheng J, Lai K, Lin C, Lo G, Hsu P, Yu H, Lin C, Chan H, Chen W, Chen T, Li W, Liang H. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study. Alimentary Pharmacology & Therapeutics 2008;28:304-11. [DOI: 10.1111/j.1365-2036.2008.03702.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
250 Moore A, Cohen-Naftaly M, Benjaminov O, Braun M, Issachar A, Mor E, Tovar A, Sarfaty M, Gordon N, Stemmer SM. Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer 2016;7:883-9. [PMID: 27313777 DOI: 10.7150/jca.14721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
251 Yoon JS, Kim G, Lee YR, Park SY, Tak WY, Kweon YO, Park JG, Lee HW, Han YS, Ha HT, Chun JM, Jang SY, Hur K. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med 2018;12:1105-14. [PMID: 30191729 DOI: 10.2217/bmm-2018-0096] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
252 Yang S, Lin Q, Lin W, Hu W, Wang G. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol 2016;14:159. [PMID: 27282382 DOI: 10.1186/s12957-016-0912-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
253 Volk M, Marrero JA. Liver Transplantation for Hepatocellular Carcinoma: Who Benefits and Who Is Harmed? Gastroenterology 2008;134:1612-4. [DOI: 10.1053/j.gastro.2008.03.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
254 Hectors SJ, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30:3759-3769. [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
255 Zhao J, Wang J, Chai S, Zhang Y, Zhang W. Elevated lactate impairs the efficacy of antiviral treatment on post-hepatectomy survival for advanced stage hepatitis B virus - related hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019;43:67-76. [PMID: 30219693 DOI: 10.1016/j.clinre.2018.08.008] [Reference Citation Analysis]
256 Min JH, Kim YK, Choi SY, Kang TW, Jeong WK, Kim K, Won HJ. Detection of recurrent hepatocellular carcinoma after surgical resection: Non-contrast liver MR imaging with diffusion-weighted imaging versus gadoxetic acid-enhanced MR imaging. Br J Radiol 2018;91:20180177. [PMID: 29927634 DOI: 10.1259/bjr.20180177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
257 Hung CL, Yen CS, Tsai HW, Su YC, Yen CJ. Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease. BMC Cancer. 2015;15:665. [PMID: 26453548 DOI: 10.1186/s12885-015-1671-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
258 Fuster J. Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? Hepat Oncol 2015;2:245-53. [PMID: 30191006 DOI: 10.2217/hep.15.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
259 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
260 Tublin ME, Redvanly RD, Smith RH. Liver Transplantation Imaging. Textbook of Gastrointestinal Radiology. Elsevier; 2008. pp. 1795-821. [DOI: 10.1016/b978-1-4160-2332-6.50099-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
261 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7:1157-1167. [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
262 Hung HC, Lee JC, Cheng CH, Wu TH, Wang YC, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci. 2017;24:559-569. [PMID: 28846835 DOI: 10.1002/jhbp.498] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
263 Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A 2010;107:2207-12. [PMID: 20133864 DOI: 10.1073/pnas.0908867107] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
264 Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41-vii48. [PMID: 22997453 DOI: 10.1093/annonc/mds225] [Cited by in Crossref: 224] [Cited by in F6Publishing: 209] [Article Influence: 28.0] [Reference Citation Analysis]
265 Zhang M, Zhang S, Yang Z, Hu J, Hu W, Sun P, Wu L, Han B. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncol Lett 2018;16:7158-65. [PMID: 30546452 DOI: 10.3892/ol.2018.9557] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
266 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 284] [Article Influence: 35.6] [Reference Citation Analysis]
267 Li R, Gong J, Xiao C, Zhu S, Hu Z, Liang J, Li X, Yan X, Zhang X, Li D, Liu W, Chong Y, Jie Y. A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma. Genomics. 2020;112:5101-5114. [PMID: 32941982 DOI: 10.1016/j.ygeno.2020.09.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
268 Yu SC, Hui JW, Hui EP, Mo F, Lee PS, Wong J, Lee KF, Lai PB, Yeo W. Embolization Efficacy and Treatment Effectiveness of Transarterial Therapy for Unresectable Hepatocellular Carcinoma: A Case-Controlled Comparison of Transarterial Ethanol Ablation with Lipiodol–Ethanol Mixture versus Transcatheter Arterial Chemoembolization. Journal of Vascular and Interventional Radiology 2009;20:352-9. [DOI: 10.1016/j.jvir.2008.12.407] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
269 Wang SY, Chen CL, Hu YC, Chi Y, Huang YH, Su CW, Jeng WJ, Liang YJ, Wu JC. High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers (Basel) 2019;11:E1549. [PMID: 31614906 DOI: 10.3390/cancers11101549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
270 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
271 Tamura S, Sugawara Y, Kokudo N. Section 4. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation: The Tokyo University Experience. Transplantation 2014;97:S17-20. [DOI: 10.1097/01.tp.0000446268.26771.59] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
272 Zha Z, Li J. MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1. Int J Mol Med 2020;46:1849-61. [PMID: 33000203 DOI: 10.3892/ijmm.2020.4729] [Reference Citation Analysis]
273 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
274 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 18.5] [Reference Citation Analysis]
275 Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519. [PMID: 20397916 DOI: 10.1586/era.10.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
276 Yao Q, Zhang H, Xiong B, Zheng C. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study. Oncotarget 2017;8:79012-22. [PMID: 29108283 DOI: 10.18632/oncotarget.20745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
277 Aufhauser DD Jr, Sadot E, Murken DR, Eddinger K, Hoteit M, Abt PL, Goldberg DS, DeMatteo RP, Levine MH. Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Ann Surg 2018;267:922-8. [PMID: 28085695 DOI: 10.1097/SLA.0000000000002135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 10.5] [Reference Citation Analysis]
278 Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther. 2010;31:415-423. [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
279 Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, Jin J, He S, Wang C. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget 2014;5:10271-9. [PMID: 25431949 DOI: 10.18632/oncotarget.2082] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
280 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
281 Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Transl Oncol 2014;7:248-55. [PMID: 24704092 DOI: 10.1016/j.tranon.2014.02.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
282 Kapitanov T, Neumann UP, Schmeding M. Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract 2015;2015:696120. [PMID: 25642245 DOI: 10.1155/2015/696120] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
283 Itri JN, Heller MT, Tublin ME. Hepatic transplantation: postoperative complications. Abdom Imaging. 2013;38:1300-1333. [PMID: 23644931 DOI: 10.1007/s00261-013-0002-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
284 Eisele RM, Schumacher G, Jonas S, Neuhaus P. Radiofrequency ablation prior to liver transplantation: focus on complications and on a rare but severe case. Clin Transplant. 2008;22:20-28. [PMID: 18217901 DOI: 10.1111/j.1399-0012.2007.00725.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
285 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 233] [Article Influence: 24.4] [Reference Citation Analysis]
286 Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean J Pathol 2013;47:130-6. [PMID: 23667372 DOI: 10.4132/KoreanJPathol.2013.47.2.130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
287 Krishnamoorthy S, Grubbs RH. Aldehyde-Functionalized Magnetic Particles to Capture Off-Target Chemotherapeutic Agents. ACS Omega 2020;5:29121-6. [PMID: 33225143 DOI: 10.1021/acsomega.0c03840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Rodríguez-Sanjuán JC, González F, Juanco C, Herrera LA, López-Bautista M, González-Noriega M, García-Somacarrera E, Figols J, Gómez-Fleitas M, Silván M. Radiological and pathological assessment of hepatocellular carcinoma response to radiofrequency. A study on removed liver after transplantation. World J Surg. 2008;32:1489-1494. [PMID: 18373117 DOI: 10.1007/s00268-008-9559-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
289 Rong Z, Lu Q, Yan J. Totally laparoscopic radiofrequency-assisted liver partition with portal vein ligation for hepatocellular carcinoma in cirrhotic liver. Medicine (Baltimore) 2017;96:e9432. [PMID: 29390573 DOI: 10.1097/MD.0000000000009432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
290 Lo C. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion. Am J Transplant. 2008;8:2485-2486. [PMID: 19032218 DOI: 10.1111/j.1600-6143.2008.02466.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
291 Zhang R, Xu L, Wen X, Zhang J, Yang P, Zhang L, Xue X, Wang X, Huang Q, Guo C, Shi Y, Niu T, Chen F. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.Quant Imaging Med Surg. 2019;9:1503-1515. [PMID: 31667137 DOI: 10.21037/qims.2019.09.07] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
292 Dwyer BJ, Olynyk JK, Ramm GA, Tirnitz-Parker JE. TWEAK and LTβ Signaling during Chronic Liver Disease. Front Immunol 2014;5:39. [PMID: 24592262 DOI: 10.3389/fimmu.2014.00039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
293 Coelho G, Vasconcelos K, Vasconcelos J, Barros M, Costa P, Borges G, Júnior J, Brasil I, Filho D, Viana C, Rocha T, Mesquita D, Garcia J. Orthotopic Liver Transplantation for Hepatocellular Carcinoma: One Center's Experience in the Northeast of Brazil. Transplantation Proceedings 2009;41:1740-2. [DOI: 10.1016/j.transproceed.2009.01.104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
294 Manizate F, Hiotis SP, Labow D, Roayaie S, Schwartz M. Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci. 2010;17:385-388. [PMID: 19936599 DOI: 10.1007/s00534-009-0228-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
295 Zhu Y, Deng M, Xu N, Xie Y, Zhang X. A Tumor Microenvironment Responsive Nanotheranostics Agent for Magnetic Resonance Imaging and Synergistic Photodynamic Therapy/Photothermal Therapy of Liver Cancer. Front Chem 2021;9:650899. [PMID: 33898391 DOI: 10.3389/fchem.2021.650899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, Darzi A, Sodergren MH, Jiao LR. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. British Journal of Surgery 2017;104:1433-42. [DOI: 10.1002/bjs.10597] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
297 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
298 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 300] [Article Influence: 31.0] [Reference Citation Analysis]
299 Han Y, Pu R, Han X, Zhao J, Li W, Yin J, Zhang Y, Shen Q, Xie J, Zhang Q. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Liver Int. 2014;34:728-736. [PMID: 24118778 DOI: 10.1111/liv.12313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
300 Lee NPY, Leung K, Cheung N, Lam BY, Xu MZ, Sham PC, Lau GK, Poon RTP, Fan ST, Luk JM. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008;8:2136-49. [DOI: 10.1002/pmic.200700590] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
301 Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol. 2007;3:429-439. [PMID: 17661718 DOI: 10.2217/14796694.3.4.429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
302 Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
303 Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554. [PMID: 17133492 DOI: 10.1002/hep.21415] [Cited by in Crossref: 252] [Cited by in F6Publishing: 237] [Article Influence: 18.0] [Reference Citation Analysis]
304 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 7.3] [Reference Citation Analysis]
305 Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R. Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Radiology. 2016;279:432-442. [PMID: 26653683 DOI: 10.1148/radiol.2015150998] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 20.5] [Reference Citation Analysis]
306 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
307 Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, Guettier C, Vallee JC, Saliba F, Bismuth H, Samuel D, Castaing D, Adam R. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes? Ann Surg. 2016;264:155-163. [PMID: 26649581 DOI: 10.1097/sla.0000000000001442] [Cited by in Crossref: 58] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
308 Lv H, Liu Y, Zhang B, Zheng Y, Ji H, Li S. The improvement effect of gastrodin on LPS/GalN-induced fulminant hepatitis via inhibiting inflammation and apoptosis and restoring autophagy. Int Immunopharmacol 2020;85:106627. [PMID: 32473572 DOI: 10.1016/j.intimp.2020.106627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
309 Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int 2012;2012:172894. [PMID: 22666632 DOI: 10.1155/2012/172894] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
310 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg. 2007;245:51-58. [PMID: 17197965 DOI: 10.1097/01.sla.] [Reference Citation Analysis]
311 Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607-620. [PMID: 24126369 DOI: 10.1148/radiol.13130498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
312 Chen LP, Li C, Wen TF, Yan LN, Li B, Yang JY. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? Pak J Med Sci 2015;31:763-9. [PMID: 26430399 DOI: 10.12669/pjms.314.7523] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
313 Fonseca AL, Cha CH. Hepatocellular carcinoma: a comprehensive overview of surgical therapy. J Surg Oncol. 2014;110:712-719. [PMID: 24894746 DOI: 10.1002/jso.23673] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
314 Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence. Journal of Hepatology 2009;51:842-4. [DOI: 10.1016/j.jhep.2009.08.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
315 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
316 Mazzotta AD, Pascale A, Cano L, Rosmorduc O, Allard MA, Sa Cunha A, Adam R, Cherqui D, Vibert E, Golse N. Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha-fetoprotein score: a new prognostic risk factor. Transpl Int 2021;34:954-63. [PMID: 33660346 DOI: 10.1111/tri.13858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep 2017;7:16978. [PMID: 29208982 DOI: 10.1038/s41598-017-17285-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
318 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
319 Mas VR, Fisher RA, Archer KJ, Yanek KC, Williams B, Dumur CI, Maluf DG. Genes Associated With Progression and Recurrence of Hepatocellular Carcinoma in Hepatitis C Patients Waiting and Undergoing Liver Transplantation: Preliminary Results. Transplantation 2007;83:973-81. [DOI: 10.1097/01.tp.0000258643.05294.0b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
320 Kim JH, Min YW, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5666. [PMID: 28002336 DOI: 10.1097/MD.0000000000005666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
321 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
322 Hao P, Yue F, Xian X, Ren Q, Cui H, Wang Y. Inhibiting effect of MicroRNA-3619-5p/PSMD10 axis on liver cancer cell growth in vivo and in vitro. Life Sci 2020;254:117632. [PMID: 32437796 DOI: 10.1016/j.lfs.2020.117632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
323 Chen Z, Chen HY, Lang QB, Li B, Zhai XF, Guo YY, Yue XQ, Ling CQ. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial. Chin J Integr Med 2012;18:339-44. [PMID: 22549390 DOI: 10.1007/s11655-012-1083-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
324 Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, Harnois DM. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant. 2010;10:1263-1267. [PMID: 20420633 DOI: 10.1111/j.1600-6143.2010.03062.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
325 Cha C. Surgical Therapy for Hepatocellular Carcinoma: Formulating a Rational Approach. Journal of Clinical Gastroenterology 2013;47:S30-6. [DOI: 10.1097/mcg.0b013e31829440bd] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
326 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004. [PMID: 18923165 DOI: 10.1056/nejmoa0804525] [Cited by in Crossref: 886] [Cited by in F6Publishing: 475] [Article Influence: 68.2] [Reference Citation Analysis]
327 Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yao S, Yagi S, Kamo N, Seo S, Taura K, Okajima H, Uemoto S. Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma. Liver Cancer 2019;8:92-109. [PMID: 31019900 DOI: 10.1159/000488779] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
328 Chen L, Chen Y, Wang X, Li H, Zhang H, Gong J, Shen S, Yin W, Hu H. Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J. 2015;14:67. [PMID: 26155840 DOI: 10.1186/s12937-015-0056-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
329 Majno P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language. Liver Transpl. 2006;12:896-898. [PMID: 16721768 DOI: 10.1002/lt.20808] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
330 Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, Masciangelo R, Catalano C, Passariello R. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251:85-95. [PMID: 19332848 DOI: 10.1148/radiol.2511080400] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
331 Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-537. [PMID: 19307789 DOI: 10.1097/tp.0b013e3181943bee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
332 Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3. [PMID: 19351279 DOI: 10.1586/egh.09.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
333 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
334 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 22.5] [Reference Citation Analysis]
335 Kim JM, Kwon CH, Joh JW, Park JB, Ko JS, Lee JH, Kim SJ, Park CK. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. World J Surg Oncol. 2013;11:40. [PMID: 23432910 DOI: 10.1186/1477-7819-11-40] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
336 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
337 Nguyen GC, Thuluvath NP, Segev DL, Thuluvath PJ. Volumes of liver transplant and partial hepatectomy procedures are independently associated with lower postoperative mortality following resection for hepatocellular carcinoma. Liver Transpl. 2009;15:776-781. [PMID: 19562711 DOI: 10.1002/lt.21767] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
338 Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1). Med Sci Monit 2019;25:3212-20. [PMID: 31041919 DOI: 10.12659/MSM.913937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
339 Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc 2021;120:1563-71. [PMID: 33334659 DOI: 10.1016/j.jfma.2020.11.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
341 Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412-418. [PMID: 21756858 DOI: 10.1016/j.jhep.2011.05.020] [Cited by in Crossref: 182] [Cited by in F6Publishing: 178] [Article Influence: 18.2] [Reference Citation Analysis]
342 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 550] [Article Influence: 44.3] [Reference Citation Analysis]
343 Zhou J, Wang Z, Qiu S, Huang X, Sun J, Gu W, Fan J. Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation. J Cancer Res Clin Oncol 2010;136:1453-60. [DOI: 10.1007/s00432-010-0802-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
344 Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM, Fan ST. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer 2006;95:1050-5. [PMID: 17008870 DOI: 10.1038/sj.bjc.6603399] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
345 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
346 Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, Murata K, Shiomi H, Naka S, Kurumi Y, Tani T, Tabata Y. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol 2012;30:62-8. [PMID: 22194039 DOI: 10.1007/s11604-011-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
347 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
348 Choi SB, Kim H, Kim SH, Park YN, Kim KS. Solitary extrahepatic intraabdominal metastasis from hepatocellular carcinoma after liver transplantation. Yonsei Med J 2011;52:199-203. [PMID: 21155056 DOI: 10.3349/ymj.2011.52.1.199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
349 Hibi T, Shinoda M, Itano O, Kitagawa Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014;10:241-9. [PMID: 24836922 DOI: 10.4161/org.29245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
350 Yu T, Han C, Zhu G, Liao X, Qin W, Yang C, Liu Z, Su H, Liu X, Yu L, Liu Z, Lu S, Chen Z, Liang Y, Huang J, Qin X, Gui Y, Li J, Peng T. Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Med 2017;6:1587-600. [PMID: 28568708 DOI: 10.1002/cam4.1077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
351 Panera N, Crudele A, Romito I, Gnani D, Alisi A. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci 2017;18:E99. [PMID: 28067792 DOI: 10.3390/ijms18010099] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
352 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
353 Inoue M, Ogasawara S, Chiba T, Ooka Y, Wakamatsu T, Kobayashi K, Suzuki E, Tawada A, Yokosuka O. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:908-15. [PMID: 27787908 DOI: 10.1111/jgh.13622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
354 Zeng JD, Zhang N, Zhao GJ, Xu LX, Yang Y, Xu XY, Chen MK, Wang HY, Zheng SX, Li XX. MT1G is Silenced by DNA Methylation and Contributes to the Pathogenesis of Hepatocellular Carcinoma. J Cancer 2018;9:2807-16. [PMID: 30123349 DOI: 10.7150/jca.25680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
355 Lym JS, Nguyen QV, Ahn DW, Huynh CT, Jae HJ, Kim YI, Lee DS. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy. Acta Biomaterialia 2016;41:253-63. [DOI: 10.1016/j.actbio.2016.05.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
356 Sant'Anna LB, Cargnoni A, Ressel L, Vanosi G, Parolini O. Amniotic membrane application reduces liver fibrosis in a bile duct ligation rat model. Cell Transplant. 2011;20:441-453. [PMID: 20719087 DOI: 10.3727/096368910X522252] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
357 Salgia RJ, Goodrich NP, Marrero JA, Volk ML. Donor Factors Similarly Impact Survival Outcome After Liver Transplantation in Hepatocellular Carcinoma and Non-hepatocellular Carcinoma Patients. Dig Dis Sci 2014;59:214-9. [DOI: 10.1007/s10620-013-2883-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
358 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Efficacy of surgical microwave ablation for recurrent hepatocellular carcinoma after curative hepatectomy. HPB 2020;22:461-9. [DOI: 10.1016/j.hpb.2019.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
359 Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95. [DOI: 10.1111/apt.14256] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
360 Moggia E, Rouse B, Simillis C, Li T, Vaughan J, Davidson BR, Gurusamy KS. Methods to decrease blood loss during liver resection: a network meta-analysis. Cochrane Database Syst Rev 2016;10:CD010683. [PMID: 27797116 DOI: 10.1002/14651858.CD010683.pub3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
361 Sugimachi K, Shirabe K, Taketomi A, Soejima Y, Iguchi T, Takeishi K, Toshima T, Aishima S, Tajima T, Maehara Y. Prognostic Significance of Preoperative Imaging in Recipients of Living Donor Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2011;91:570-4. [DOI: 10.1097/tp.0b013e318208134e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
362 Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012;7:e52393. [PMID: 23285022 DOI: 10.1371/journal.pone.0052393] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
363 Tang B, Qi G, Sun X, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J. HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail. Mol Cancer. 2016;15:57. [PMID: 27600149 DOI: 10.1186/s12943-016-0540-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
364 Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS, Cameron A, Ghobrial M, Kam I, Busuttil R. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant. 2013;27:829-837. [PMID: 24033475 DOI: 10.1111/ctr.12224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
365 Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:34-39. [PMID: 27775949 DOI: 10.1097/rlu.0000000000001449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
366 Schwartz M. Liver transplantation: the preferred treatment for early hepatocellular carcinoma in the setting of cirrhosis? Ann Surg Oncol 2007;14:548-52. [PMID: 17009143 DOI: 10.1245/s10434-006-9157-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
367 Grazi GL. Liver resections: complications and survival outcome. Expert Rev Pharmacoecon Outcomes Res 2007;7:269-79. [PMID: 20528313 DOI: 10.1586/14737167.7.3.269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
368 Kim BY, Choi DW, Woo SR, Park ER, Lee JG, Kim SH, Koo I, Park SH, Han CJ, Kim SB, Yeom YI, Yang SJ, Yu A, Lee JW, Jang JJ, Cho MH, Jeon WK, Park YN, Suh KS, Lee KH. Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma. BMC Genomics 2015;16:279. [PMID: 25888140 DOI: 10.1186/s12864-015-1472-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
369 Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Roenn NMV, Berkes JL, Cotler SJ. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Annals of Hepatology 2013;12:766-73. [DOI: 10.1016/s1665-2681(19)31318-3] [Cited by in Crossref: 21] [Article Influence: 2.6] [Reference Citation Analysis]
370 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
371 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
372 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
373 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
374 Agüero F, Forner A, Valdivieso A, Blanes M, Barcena R, Manzardo C, Rafecas A, Castells L, Abradelo M, Barrera-Baena P, González-Diéguez L, Salcedo M, Serrano T, Jiménez-Pérez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM; FIPSE Investigators. Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. Liver Transpl 2017;23:645-51. [PMID: 28188668 DOI: 10.1002/lt.24741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
375 Thelen A, Jonas S, Benckert C, Weichert W, Schott E, Bötcher C, Dietz E, Wiedenmann B, Neuhaus P, Scholz A. Tumor-associated lymphangiogenesis correlates with prognosis after resection of human hepatocellular carcinoma. Ann Surg Oncol 2009;16:1222-30. [PMID: 19224279 DOI: 10.1245/s10434-009-0380-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
376 Sarpel U, Suprun M, Sofianou A, Berger Y, Tedjasukmana A, Sekendiz Z, Bagiella E, Schwartz ME. Disentangling the effects of race and socioeconomic factors on liver transplantation rates for hepatocellular carcinoma. Clin Transplant 2016;30:714-21. [PMID: 27027869 DOI: 10.1111/ctr.12739] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
377 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
378 Li H, Zhang L. Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy. Oncotarget 2017;8:1805-13. [PMID: 27655683 DOI: 10.18632/oncotarget.12101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
379 Lencioni R, Crocetti L, Petruzzi P, Vignali C, Bozzi E, Della Pina C, Bargellini I, Cioni D, Oliveri F, De Simone P, Bartolozzi C, Brunetto M, Filipponi F. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. Journal of Hepatology 2008;49:217-22. [DOI: 10.1016/j.jhep.2008.03.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
380 Du Z, Li B, Wei Y, Yin J, Feng X, Chen X. A new scoring system for assessment of liver function after successful hepatectomy in patients with hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2011;10:265-9. [DOI: 10.1016/s1499-3872(11)60044-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
381 Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-hagen M, Neumann U, Schoening W. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary & Pancreatic Diseases International 2019;18:228-36. [DOI: 10.1016/j.hbpd.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
382 Sabaté-Llobera A, Mestres-Martí J, Reynés-Llompart G, Lladó L, Mils K, Serrano T, Cortés-Romera M, Bertran E, Fabregat I, Ramos E. 2-[18F]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2554. [PMID: 34070953 DOI: 10.3390/cancers13112554] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Zhang Y, Li Y, Jiang W, Li Q, Lan Y. The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset. Medicine (Baltimore) 2019;98:e14810. [PMID: 30921182 DOI: 10.1097/MD.0000000000014810] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
384 Ahn S, Hyeon J, Park CK. Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver 2013;7:206-12. [PMID: 23560157 DOI: 10.5009/gnl.2013.7.2.206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
385 Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL, Park CK. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol. 2013;20:3747-3753. [PMID: 23800896 DOI: 10.1245/s10434-013-3070-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
386 Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, Van Vlierberghe H, Defreyne L. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011;38:2117-24. [DOI: 10.1007/s00259-011-1881-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
387 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
388 Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol. 2017;23:7415-7424. [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
389 Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW. Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol 2010;17:3104-11. [PMID: 20585872 DOI: 10.1245/s10434-010-1181-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
390 Wang Z, Jiang C, Chen W, Zhang G, Luo D, Cao Y, Wu J, Ding Y, Liu B. Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells. Biomed Res Int. 2014;2014:732516. [PMID: 24995326 DOI: 10.1155/2014/732516] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
391 Cheng Q, Tong TJ, Li Z, Hu SH, Chen DB, Wang SQ, Zhu JY. Paradoxical effects of cellular senescence-inhibited gene involved in hepatocellular carcinoma migration and proliferation by ERK pathway and mesenchymal-like markers. Onco Targets Ther 2019;12:2035-46. [PMID: 30936720 DOI: 10.2147/OTT.S188449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
392 Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF) - Recent advances in prevention and clinical management. Eur J Surg Oncol 2021;47:216-24. [PMID: 32943278 DOI: 10.1016/j.ejso.2020.09.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
393 Ha SY, Song DH, Lee JJ, Lee HW, Cho SY, Park CK. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver 2014;8:648-54. [PMID: 25287169 DOI: 10.5009/gnl13406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
394 Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647-3655. [PMID: 24002499 DOI: 10.1200/jco.2012.48.5896] [Cited by in Crossref: 158] [Cited by in F6Publishing: 77] [Article Influence: 19.8] [Reference Citation Analysis]
395 Hu H, Wang Z, Huang X, Chen S, Zheng X, Ruan S, Xie X, Lu M, Yu J, Tian J, Liang P, Wang W, Kuang M. Ultrasound-based radiomics score: a potential biomarker for the prediction of microvascular invasion in hepatocellular carcinoma. Eur Radiol 2019;29:2890-901. [DOI: 10.1007/s00330-018-5797-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
396 Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012;56:855-861. [PMID: 22178270 DOI: 10.1016/j.jhep.2011.11.017] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
397 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 12.9] [Reference Citation Analysis]
398 Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, Grant DR, Greig PD. Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma. J Gastrointest Surg. 2007;11:589-595. [PMID: 17393258 DOI: 10.1007/s11605-007-0154-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
399 Li Z, Zhou Q, Zhou J, Duan X, Zhu J, Wang TD. In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide. Biomed Opt Express 2016;7:3163-9. [PMID: 27699089 DOI: 10.1364/BOE.7.003163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
400 Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep 2021;11:5303. [PMID: 33674622 DOI: 10.1038/s41598-021-84117-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
401 Trinchet JC, Ganne-Carrié N, Nahon P, N'kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 2007;13:2455-60. [PMID: 17552029 DOI: 10.3748/wjg.v13.i17.2455] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
402 Beaugrand M, Trinchet JC. [Non-surgical treatment of hepatocellular carcinoma. An overview]. Cancer Radiother 2005;9:464-9. [PMID: 16236541 DOI: 10.1016/j.canrad.2005.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
403 Gwiasda J, Schulte A, Kaltenborn A, Ramackers W, Kleine M, Beetz O, Klempnauer J, Emmanouilidis N, Schrem H. Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. Surg Oncol 2017;26:178-87. [PMID: 28577724 DOI: 10.1016/j.suronc.2017.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
404 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
405 González R, De la Rosa ÁJ, Rufini A, Rodríguez-Hernández MA, Navarro-Villarán E, Marchal T, Pereira S, De la Mata M, Müller-Schilling M, Pascasio-Acevedo JM, Ferrer-Ríos MT, Gómez-Bravo MA, Padillo FJ, Muntané J. Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS One 2017;12:e0174326. [PMID: 28350813 DOI: 10.1371/journal.pone.0174326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
406 Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl. 2013;19:1020-1029. [PMID: 23852663 DOI: 10.1002/lt.23703] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
407 Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma. European Journal of Medicinal Chemistry 2019;183:111706. [DOI: 10.1016/j.ejmech.2019.111706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
408 Cha HJ, Kim J, Hong SM, Hong SJ, Park JH, Kim E, Wang H, Choi YJ, Do I, Joh JW, Kim DS, Choi KY. Overexpression of Renal Tumor Antigen Is Associated with Tumor Invasion and Poor Prognosis of Hepatocellular Carcinoma. Ann Surg Oncol 2012;19:404-11. [DOI: 10.1245/s10434-011-1856-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
409 Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. Digestive and Liver Disease 2010;42:S249-57. [DOI: 10.1016/s1590-8658(10)60513-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
410 Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969. [PMID: 27446846 DOI: 10.1155/2016/5234969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
411 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
412 Lv Y, Wei W, Huang Z, Chen Z, Fang Y, Pan L, Han X, Xu Z. Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection: LncRNA expression profile to predict HCC recurrence. Hepatol Res 2018;48:1140-8. [DOI: 10.1111/hepr.13220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
413 Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J Pineal Res 2017;62:e12398. [DOI: 10.1111/jpi.12398] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
414 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 21.6] [Reference Citation Analysis]
415 Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C. Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract 2013;2013:782581. [PMID: 24194752 DOI: 10.1155/2013/782581] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
416 Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol. 2014;20:7525-7533. [PMID: 24976693 DOI: 10.3748/wjg.v20.i24.7525] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
417 Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, Mikagi K, Saitsu H. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. Hepatol Int 2018;12:149-57. [DOI: 10.1007/s12072-018-9851-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
418 Baccarani U, Isola M, Adani GL, Benzoni E, Avellini C, Lorenzin D, Bresadola F, Uzzau A, Risaliti A, Beltrami AP, Soldano F, De Anna D, Bresadola V. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transplant Int 2008;21:247-54. [DOI: 10.1111/j.1432-2277.2007.00597.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
419 Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res. 2014;44:259-269. [PMID: 23607290 DOI: 10.1111/hepr.12115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
420 Poté N, Cros J, Laouirem S, Raffenne J, Negrão M, Albuquerque M, Bedossa P, Godinho Ferreira M, Ait Si Ali S, Fior R, Paradis V. The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma. Liver Int 2020;40:956-67. [PMID: 31943753 DOI: 10.1111/liv.14381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
421 Sort P, Álvarez MA, Bargalló A, Isava Á, Muñoz M, Porta F, Rodríguez E, Vida F. Coste del cribado del hepatocarcinoma en pacientes cirróticos: un estudio prospectivo. Gastroenterología y Hepatología 2011;34:519-23. [DOI: 10.1016/j.gastrohep.2011.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
422 Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598-609. [PMID: 17462459 DOI: 10.1016/j.surg.2006.11.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
423 Liu X, Li G, Ai L, Ye Q, Yu T, Yang B. Prognostic value of ATAD3 gene cluster expression in hepatocellular carcinoma. Oncol Lett 2019;18:1304-10. [PMID: 31423190 DOI: 10.3892/ol.2019.10454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
424 Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M, Goldenberg D, Sonnenblick A, Peled A, Rose-John S, Galun E, Axelrod JH. Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 2017;65:1600-11. [PMID: 28027584 DOI: 10.1002/hep.29004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
425 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
426 Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, Seo S, Machimoto T, Uemoto S. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142:685-694. [PMID: 17981188 DOI: 10.1016/j.surg.2007.05.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 5.4] [Reference Citation Analysis]
427 Covey AM, Maluccio MA, Schubert J, BenPorat L, Brody LA, Sofocleous CT, Getrajdman GI, Fong Y, Brown KT. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer. 2006;106:2181-2189. [PMID: 16596622 DOI: 10.1002/cncr.21883] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
428 Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012;46:796-801. [PMID: 22955262 DOI: 10.1097/mcg.0b013e3182641806] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
429 Lencioni R, Crocetti L, Cioni D, Pina CD, Oliveri F, De Simone P, Brunetto M, Filipponi F. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol. 2010;21:1533-1538. [PMID: 20817558 DOI: 10.1016/j.jvir.2010.06.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
430 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4160. [PMID: 27472685 DOI: 10.1097/MD.0000000000004160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
431 Dutkowski P, Linecker M, Deoliveira ML, Müllhaupt B, Clavien P. Challenges to Liver Transplantation and Strategies to Improve Outcomes. Gastroenterology 2015;148:307-23. [DOI: 10.1053/j.gastro.2014.08.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 22.5] [Reference Citation Analysis]
432 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
433 Gray WH, Patel R, Baker CJ, Starnes VA, Bowdish ME. Resection of Metastatic Hepatocellular Carcinoma in the Ventricular Septum Causing Left Ventricular Outflow Tract Obstruction. Ann Thorac Surg 2018;105:e107-8. [PMID: 29455819 DOI: 10.1016/j.athoracsur.2017.09.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
434 Song SK, Park MG, Park SK, Chung CW, Park Y. MicroRNAs associated with microvascular invasion in hepatocellular carcinoma and their prognostic impacts in patients undergoing hepatic resection. Oncol Lett 2019;18:6293-303. [PMID: 31788107 DOI: 10.3892/ol.2019.10987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
435 Wang Q, Jiang Y, Guo R, Lv R, Liu T, Wei H, Ming H, Tian X. Physcion 8-O-β-glucopyranoside suppresses tumor growth of Hepatocellular carcinoma by downregulating PIM1. Biomed Pharmacother 2017;92:451-8. [PMID: 28570979 DOI: 10.1016/j.biopha.2017.05.110] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
436 Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JPA, Prasad KR. Preoperative Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor after Curative Resection for Hepatocellular Carcinoma. World J Surg 2008;32:1757-62. [DOI: 10.1007/s00268-008-9552-6] [Cited by in Crossref: 278] [Cited by in F6Publishing: 275] [Article Influence: 21.4] [Reference Citation Analysis]
437 Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, Pesenti C, Ratone JP, Bernard JP, Gerolami R, Giovannini M. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21-7. [PMID: 26056497 DOI: 10.2147/HMER.S67940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
438 McLennan G, Bennett SL, Ju S, Babsky A, Bansal N, Shorten ML, Levitin S, Bonnac L, Panciewicz KW, Jayaram HN. Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside. Cardiovasc Intervent Radiol 2012;35:645-52. [PMID: 21431971 DOI: 10.1007/s00270-011-0140-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
439 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
440 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
441 Dai Z, Yu L, Zhou J, Qiu SJ, Fan J. Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation? Expert Rev Gastroenterol Hepatol 2009;3:211-3. [PMID: 19485802 DOI: 10.1586/egh.09.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
442 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
443 Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. J Dig Dis. 2013;14:552-558. [PMID: 23782458 DOI: 10.1111/1751-2980.12083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
444 Peck-Radosavljevic M. Hepatocellular carcinoma: the place of new medical therapies. Therap Adv Gastroenterol 2010;3:259-67. [PMID: 21180607 DOI: 10.1177/1756283X10362278] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
445 Simillis C, Li T, Vaughan J, Becker LA, Davidson BR, Gurusamy KS. Methods to decrease blood loss during liver resection: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010683. [PMID: 24696014 DOI: 10.1002/14651858.CD010683.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
446 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006] [Cited by in Crossref: 254] [Cited by in F6Publishing: 238] [Article Influence: 25.4] [Reference Citation Analysis]
447 Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-cisneros J, Gonzalez-dieguez L, Salcedo M, Serrano T, Jimenez-perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM; the FIPSE Investigators. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology 2016;63:488-98. [DOI: 10.1002/hep.28321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
448 Tanwar S, Khan SA, Grover VP, Gwilt C, Smith B, Brown A. Liver transplantation for hepatocellular carcinoma. World J Gastroenterol. 2009;15:5511-5516. [PMID: 19938188 DOI: 10.3748/wjg.15.5511] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
449 Hamaguchi Y, Kaido T, Okumura S, Ito T, Fujimoto Y, Ogawa K, Mori A, Hammad A, Hatano E, Uemoto S. Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2015;22:475-85. [PMID: 25755128 DOI: 10.1002/jhbp.236] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
450 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
451 Wan L, Guo L, Hu Y, Huang H, Zhang M, Xu K, De G, Zheng F, Wu Z, Hu C, Wen Z. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer. Clin Biochem 2021;89:44-50. [PMID: 33309517 DOI: 10.1016/j.clinbiochem.2020.12.005] [Reference Citation Analysis]
452 Truong L, Tat J, Booy M, Le A, Marasigan JM, Yuan C, Zeng A, Panchal A, Sadler GR. The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules. J Cancer Educ 2016;31:292-300. [PMID: 25971431 DOI: 10.1007/s13187-015-0836-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
453 Zhong XG, He S, Yin W, Deng JY, Cheng B. Selective tropism of liver stem cells to hepatocellular carcinoma in vivo. World J Gastroenterol 2007;13:3886-91. [PMID: 17657848 DOI: 10.3748/wjg.v13.i28.3886] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
454 Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114. [PMID: 23941866 DOI: 10.1038/mtna.2013.43] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
455 Wang W, Liu G, Chen L, Wang Z, Zhou L, Lu M, Xie X, Huang Y, Li W. Preliminary experience of a new perspective view technology for the detection of portal vein thrombus in hepatocellular carcinoma patients. Abdom Imaging 2014;39:1145-52. [DOI: 10.1007/s00261-014-0145-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
456 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 14.2] [Reference Citation Analysis]
457 Erstad DJ, Tanabe KK. Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:1474-93. [DOI: 10.1245/s10434-019-07227-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 22.0] [Reference Citation Analysis]
458 Young S, Chau G, Lee I, Yeh Y, Chao Y, Huo T, Su C, Lin H, Hou M, Lee M, Huang Y. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association 2020;119:218-29. [DOI: 10.1016/j.jfma.2019.04.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
459 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
460 Mergental H, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 2010;23:662-7. [PMID: 20345561 DOI: 10.1111/j.1432-2277.2010.01076.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
461 Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2008;66:200-7. [DOI: 10.1016/j.critrevonc.2008.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
462 Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031. [PMID: 23166535 DOI: 10.5812/hepatmon.6031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
463 Li J, Zhou M, Liu F, Xiong C, Wang W, Cao Q, Wen X, Robertson JD, Ji X, Wang YA, Gupta S, Li C. Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats. Radiology 2016;281:427-35. [PMID: 27347765 DOI: 10.1148/radiol.2016152510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
464 Pahade JK, Juice D, Staib L, Israel G, Cornfeld D, Mitchell K, Weinreb J. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies? Abdom Radiol 2016;41:1270-84. [DOI: 10.1007/s00261-016-0635-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
465 Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47:9-15. [PMID: 23482400 DOI: 10.4132/koreanjpathol.2013.47.1.9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
466 Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther 2016;10:2461-6. [PMID: 27536066 DOI: 10.2147/DDDT.S113295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
467 Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int 2014;13:153-61. [PMID: 24686542 DOI: 10.1016/s1499-3872(14)60025-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 5.1] [Reference Citation Analysis]
468 Rich N, Tanriover B, Singal AG, Marrero JA. Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. Transplantation. 2017;101:e12-e19. [PMID: 28009759 DOI: 10.1097/tp.0000000000001515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
469 Decaens T, Hurtova M, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2009;33:61-9. [DOI: 10.1016/j.gcb.2008.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
470 Matsukuma S, Sakamoto K, Tokuhisa Y, Tokumitsu Y, Matsui H, Kanekiyo S, Tomochika S, Iida M, Suzuki N, Takeda S, Ueno T, Wada H, Kobayashi S, Saeki I, Eguchi H, Sakon M, Sakaida I, Nagano H. Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer-B hepatocellular carcinoma. Oncol Lett 2018;16:6383-92. [PMID: 30344760 DOI: 10.3892/ol.2018.9420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
471 Huang M, Liao B, Xu P, Cai H, Huang K, Dong Z, Xu L, Peng Z, Luo Y, Zheng K, Peng B, Li ZP, Feng ST. Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Preoperative Gd-EOB-DTPA-Dynamic Enhanced MRI and Histopathological Correlation. Contrast Media Mol Imaging. 2018;2018:9674565. [PMID: 29606926 DOI: 10.1155/2018/9674565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
472 Li L, Li B, Zhang M. Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. Acta Radiol 2020;61:723-31. [PMID: 31594382 DOI: 10.1177/0284185119878357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Yang L, Gu D, Wei J, Yang C, Rao S, Wang W, Chen C, Ding Y, Tian J, Zeng M. A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Liver Cancer. 2019;8:373-386. [PMID: 31768346 DOI: 10.1159/000494099] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
474 Chan J, Ko FC, Yeung YS, Ng IO, Yam JW. Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One 2011;6:e16984. [PMID: 21347395 DOI: 10.1371/journal.pone.0016984] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
475 Ha SY, Yu JI, Choi C, Kang SY, Joh JW, Paik SW, Kim S, Kim M, Park HC, Park CK. Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma. Sci Rep 2019;9:14738. [PMID: 31611609 DOI: 10.1038/s41598-019-50594-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
476 Wang Z, Liu G, Lu MD, Xie X, Kuang M, Wang W, Xu Z, Lin M, Chen L. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma. Ultrasound Med Biol 2015;41:1277-86. [PMID: 25623820 DOI: 10.1016/j.ultrasmedbio.2014.12.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
477 Liu S, Xu M, Zhu C, Zhao Q, Zhou F. Taste receptor T1R1/T1R3 promotes the tumoricidal activity of hepatic CD49a+ CD49b- natural killer cells. Eur J Immunol 2018;48:2031-41. [PMID: 30259960 DOI: 10.1002/eji.201847688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
478 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS One 2018;13:e0202650. [PMID: 30180193 DOI: 10.1371/journal.pone.0202650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
479 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
480 Tinguely P, Fusaglia M, Freedman J, Banz V, Weber S, Candinas D, Nilsson H. Laparoscopic image-based navigation for microwave ablation of liver tumors-A multi-center study.Surg Endosc. 2017;31:4315-4324. [PMID: 28342124 DOI: 10.1007/s00464-017-5458-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
481 Bryant R, Laurent A, Tayar C, van Nhieu JT, Luciani A, Cherqui D. Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:607-33, ix. [PMID: 18486886 DOI: 10.1016/j.soc.2008.02.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
482 Mullath A, Krishna M. Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg 2019;11:287-95. [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
483 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 62] [Article Influence: 24.3] [Reference Citation Analysis]
484 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
485 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 2014;192:402-408. [PMID: 24998425 DOI: 10.1016/j.jss.2014.05.078] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
486 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
487 Lin YH, Chiou YY, Chou YH, Chau GY, Wang HK, Chiang JH, Chang CY. Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients: prognostic factors analysis. Eur J Gastroenterol Hepatol 2011;23:1239-44. [PMID: 21941191 DOI: 10.1097/MEG.0b013e32834c5b13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
488 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
489 Liu ZZ, Yan LN, Dong CN, Ma N, Yuan MN, Zhou J, Gao P. Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: An integrated analysis of gene expression profiles. Saudi J Gastroenterol 2019;25:167-75. [PMID: 30971588 DOI: 10.4103/sjg.SJG_290_18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
490 Llovet JM. Clinical and molecular classification of hepatocellular carcinoma. Liver Transpl 2007;13:S13-6. [PMID: 17969094 DOI: 10.1002/lt.21325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
491 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
492 Martin AP. Management of hepatocellular carcinoma in the age of liver transplantation. Int J Surg 2009;7:324-9. [PMID: 19643691 DOI: 10.1016/j.ijsu.2008.12.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
493 Aljabiri MR, Lodato F, Burroughs AK. Surveillance and diagnosis for hepatocellular carcinoma. Liver Transpl 2007;13:S2-S12. [DOI: 10.1002/lt.21324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
494 Vasuri F, Renzulli M, Fittipaldi S, Brocchi S, Clemente A, Cappabianca S, Bolondi L, Golfieri R, D'Errico A. Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. Sci Rep 2019;9:14749. [PMID: 31611584 DOI: 10.1038/s41598-019-51303-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
495 Zhong JH, Rodríguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 2015;94:e396. [PMID: 25621684 DOI: 10.1097/MD.0000000000000396] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
496 Tang C, Feng W, Qin L, Bao Y. Chinese Herbal Medicine, Jian Pi Li Gan Decoction, Improved Survival of Nonresectable Hepatocellular Cancer After Radiofrequency Ablation: A Retrospective Study. Integr Cancer Ther 2018;17:431-6. [PMID: 28745082 DOI: 10.1177/1534735417722223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
497 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
498 Ha SY, Kim JH, Yang JW, Kim J, Kim B, Park CK. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis. Cancer Res Treat 2016;48:1065-73. [PMID: 26511806 DOI: 10.4143/crt.2015.302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
499 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
500 Mima K, Beppu T, Ishiko T, Chikamoto A, Nakagawa S, Hayashi H, Watanabe M, Sakamaki K, Baba H. Preoperative serum hyaluronic acid level as a prognostic factor in patients undergoing hepatic resection for hepatocellular carcinoma. British Journal of Surgery 2014;101:269-76. [DOI: 10.1002/bjs.9343] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
501 Pelletier SJ, Fu S, Thyagarajan V, Romero-marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data: Liver Transplantation for HCC. Liver Transpl 2009;15:859-68. [DOI: 10.1002/lt.21778] [Cited by in Crossref: 112] [Cited by in F6Publishing: 97] [Article Influence: 9.3] [Reference Citation Analysis]
502 Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858. [PMID: 20659285 DOI: 10.1111/j.1365-2036.2010.04414.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
503 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
504 Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors: Introduction to the International Working Group Report. American Journal of Clinical Oncology 2012;35:81-90. [DOI: 10.1097/coc.0b013e3181ec60b8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
505 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
506 Sun JX, Shi J, Li N, Guo WX, Wu MC, Lau WY, Cheng SQ. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med 2016;13:452-8. [PMID: 28154776 DOI: 10.20892/j.issn.2095-3941.2016.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
507 Choi GH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Lee WJ, Han KH, Chon CY, Kim BR. The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2009;24:391-8. [DOI: 10.1111/j.1440-1746.2008.05637.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
508 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
509 Lu D, Bai X, Zou Q, Gan Z, Lv Y. Identification of the association between HMMR expression and progression of hepatocellular carcinoma via construction of a co-expression network. Oncol Lett 2020;20:2645-54. [PMID: 32765791 DOI: 10.3892/ol.2020.11844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
510 Bhandare MS, Patkar S, Shetty N, Polnaya A, Kulkarni S, Dusane RR, Shrikhande SV, Goel M. Liver resection for HCC outside the BCLC criteria. Langenbecks Arch Surg. 2018;403:37-44. [PMID: 29199380 DOI: 10.1007/s00423-017-1640-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
511 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
512 Gnani D, Romito I, Artuso S, Chierici M, De Stefanis C, Panera N, Crudele A, Ceccarelli S, Carcarino E, D'Oria V, Porru M, Giorda E, Ferrari K, Miele L, Villa E, Balsano C, Pasini D, Furlanello C, Locatelli F, Nobili V, Rota R, Leonetti C, Alisi A. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Cell Death Differ 2017;24:889-902. [PMID: 28338656 DOI: 10.1038/cdd.2017.34] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
513 Liu B, Yu S. RETRACTED: Amentoflavone suppresses hepatocellular carcinoma by repressing hexokinase 2 expression through inhibiting JAK2/STAT3 signaling. Biomedicine & Pharmacotherapy 2018;107:243-53. [DOI: 10.1016/j.biopha.2018.07.177] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
514 Zhang J, Lin H, Wang XY, Zhang DQ, Chen JX, Zhuang Y, Zheng XL. Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma. Cancer Biomark. 2017;19:257-262. [PMID: 28436387 DOI: 10.3233/cbm-160357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
515 Ng KT, Lee TK, Cheng Q, Wo JY, Sun CK, Guo DY, Lim ZX, Lo CM, Poon RT, Fan ST, Man K. Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int J Cancer 2010;127:859-72. [PMID: 20013809 DOI: 10.1002/ijc.25105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
516 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
517 Kim SH, Choi SB, Lee JG, Kim SU, Park MS, Kim do Y, Choi JS, Kim KS. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011;15:598-607. [PMID: 21336497 DOI: 10.1007/s11605-011-1452-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
518 Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J Surg Oncol. 2013;11:240. [PMID: 24060218 DOI: 10.1186/1477-7819-11-240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
519 Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. Mol Imaging Biol. 2016;18:924-934. [PMID: 27677886 DOI: 10.1007/s11307-016-1007-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
520 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 200] [Article Influence: 23.3] [Reference Citation Analysis]
521 Yang HD, Eun JW, Lee KB, Shen Q, Kim HS, Kim SY, Seo DW, Park WS, Lee JY, Nam SW. T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma. Exp Mol Med 2018;50:e420. [PMID: 29303507 DOI: 10.1038/emm.2017.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
522 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
523 Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. Journal of Hepatology 2019;70:440-8. [DOI: 10.1016/j.jhep.2018.10.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
524 Kim TM, Lee JM, Yoon JH, Joo I, Park SJ, Jeon SK, Schmidt B, Martin S. Prediction of microvascular invasion of hepatocellular carcinoma: value of volumetric iodine quantification using preoperative dual-energy computed tomography. Cancer Imaging 2020;20:60. [PMID: 32811570 DOI: 10.1186/s40644-020-00338-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Vilgrain V. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci. 2010;17:374-379. [PMID: 19924373 DOI: 10.1007/s00534-009-0230-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
526 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
527 Chen XB, Zheng XB, Cai ZX, Lin XJ, Xu MQ. MicroRNA-203 promotes liver regeneration after partial hepatectomy in cirrhotic rats. J Surg Res. 2017;211:53-63. [PMID: 28501131 DOI: 10.1016/j.jss.2016.11.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
528 Alexander ES, Wolf FJ, Machan JT, Charpentier KP, Beland MD, Iannuccilli JD, Haas RH, Dupuy DE. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. Eur J Radiol 2015;84:1083-90. [PMID: 25818732 DOI: 10.1016/j.ejrad.2015.02.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
529 Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:75-85. [PMID: 27350573 DOI: 10.1016/j.clinre.2016.05.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
530 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
531 Qin XY, Wei F, Tanokura M, Ishibashi N, Shimizu M, Moriwaki H, Kojima S. The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells. PLoS One 2013;8:e82860. [PMID: 24376596 DOI: 10.1371/journal.pone.0082860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
532 Zhu GQ, Shi KQ, Yu HJ, He SY, Braddock M, Zhou MT, Chen YP, Zheng MH. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget. 2015;6:18151-18161. [PMID: 26061709 DOI: 10.18632/oncotarget.4098] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
533 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
534 Koh YW, Park YS, Kang HJ, Shim JH, Yu E. MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma. Tumour Biol. 2015;36:4993-5000. [PMID: 25874493 DOI: 10.1007/s13277-015-3150-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
535 Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:4145-4149. [PMID: 22919246 DOI: 10.3748/wjg.v18.i31.4145] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
536 Black AP, Mehta AS. The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome. Curr Opin Pharmacol. 2018;41:74-78. [PMID: 29772420 DOI: 10.1016/j.coph.2018.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
537 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
538 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 8.1] [Reference Citation Analysis]
539 Li J, Liao Y, Suo L, Zhu P, Chen X, Dang W, Liao M, Qin L, Liao W. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep 2017;7:9229. [PMID: 28835713 DOI: 10.1038/s41598-017-09696-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
540 Luo CS, Lin Y, Zhou WP, Shi J. Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. Eur J Gastroenterol Hepatol 2020;32:1030-5. [PMID: 31764404 DOI: 10.1097/MEG.0000000000001610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
541 Fang Y, He J, Janssen HL, Wu J, Dong L, Shen XZ. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. Journal of Digestive Diseases 2018;19:155-69. [DOI: 10.1111/1751-2980.12580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
542 Avellini C, Orsaria M, Baccarani U, Adani GL, Lorenzin D, Bresadola V, Bresadola F, Beltrami CA. Apurinic apyrimidinic endonuclease/redox effector factor 1 immunoreactivity and grading in hepatocellular carcinoma risk of relapse after liver transplantation. Transplant Proc. 2010;42:1204-1208. [PMID: 20534262 DOI: 10.1016/j.transproceed.2010.03.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
543 Huang JT, Liu SM, Ma H, Yang Y, Zhang X, Sun H, Zhang X, Xu J, Wang J. Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of Hepatocellular Carcinoma. J Cell Physiol. 2016;231:328-335. [PMID: 26291451 DOI: 10.1002/jcp.25135] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
544 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
545 Ha SY, Kim JH, Yang JW, Bae H, Cho HY, Park C. Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma. Pathology - Research and Practice 2016;212:616-21. [DOI: 10.1016/j.prp.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
546 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative prognostic nutritional index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Am J Surg 2016;212:122-7. [PMID: 26421412 DOI: 10.1016/j.amjsurg.2015.06.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
547 Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR, Greig PD. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol. 2007;14:2608-2614. [PMID: 17522942 DOI: 10.1245/s10434-007-9443-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
548 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
549 Numico G, Longo V, Courthod G, Silvestris N. Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol 2015;27:351-7. [PMID: 26049277 DOI: 10.1097/CCO.0000000000000203] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]